Pentoxifylline added to methotrexate for rheumatoid arthritis
Tests pentoxifylline with methotrexate in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
Key facts
- Where
- Damietta, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06998628, who can take part
Where in Egypt
- Faculty of Medicine, Al-Azhar UniversityDamietta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT06998628
- Record updated
- 5 October 2026
- Original description
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected jointsRead full original descriptionShow less
Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Inclusion: Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [9] i.e., 28 joints disease activity score (DAS 28) >2.6; Patients receiving the conventional DMARDs; Both sexes; Age range between 18and 70 years old.
Exclusion: Patients receiving biological or synthetic DMARDs; Patients with retinal or cerebral hemorrhage; Patients with hypersensitivity to study medications; Patients with renal and hepatic dysfunction; Pregnant and lactating females.